CITIUS ONCOLOGY, INC.
Business
Citius Oncology is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its lead product is LYMPHIR (denileukin diftitox), an engineered IL-2 diphtheria toxin fusion protein approved by the FDA in August 2024 for treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), launched in December 2025. The company commercializes LYMPHIR independently in the U.S. through a dedicated sales force targeting major cancer centers and key oncologists, while pursuing partnerships for international markets. LYMPHIR is distributed through Cardinal Health, Cencora, and McKesson, with named patient programs established in select European and Middle Eastern territories.
Summary from 10-K filed 2025-12-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenues | — | — | — | — | — | |
| Research and development | 6 | 5 | — | 4 | — | |
| General and administrative | 9 | 8 | 1 | 6 | 138,115 | |
| Stock-based compensation general and administrative | 8 | 7 | — | 2 | — | |
| Total Operating Expenses | 24 | 21 | — | 12 | — | |
| Operating Loss | −24 | −21 | −1 | — | −138,115 | |
| Interest income | 36,373 | — | — | — | — | |
| Interest expense | −218,032 | — | — | — | — | |
| Total Other Income (Expense), Net | −181,659 | — | 3 | — | 518,926 | |
| Loss before Income Taxes | −24 | −21 | — | −12 | — | |
| Income tax expense | 1 | 576,000 | — | 576,000 | — | |
| Net Loss | −25 | −21 | 2 | −13 | 380,811 | |
| Net Loss Per Share - Basic (in Dollars per share) | −0.34 | −0.31 | 0.27 | −0.19 | 0.12 | |
| Net Loss Per Share Diluted (in Dollars per share) | −0.34 | −0.31 | 0.27 | −0.19 | 0.12 | |
| Weighted Average Common Shares Outstanding Basic (in Shares) | 73 | 68 | 7 | 68 | 1 | |
| Weighted Average Common Shares Outstanding Diluted (in Shares) (in Shares) | 73 | 68 | 7 | 68 | 1 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 112 | — | — | — | |
| Inventory | 22 | 8 | — | — | — | |
| Prepaid expenses | 1 | 3 | 25,454 | 8 | 88,169 | |
| Total Current Assets | 28 | 11 | 58,200 | 8 | 377,344 | |
| In-process research and development | 73 | 73 | — | 40 | — | |
| Total Other Assets | 73 | 73 | — | 40 | — | |
| Total Assets | 101 | 84 | 73 | 48 | 68 | |
| Accounts payable | 13 | 4 | — | 1 | — | |
| License payable | 23 | 28 | — | — | — | |
| Accrued expenses | 4 | — | 375,886 | 259,071 | — | |
| Total Current Liabilities | 49 | 33 | 2 | 21 | 31,836 | |
| Deferred tax liability | 3 | 2 | — | 1 | — | |
| Total Liabilities | 56 | 38 | — | 22 | — | |
| Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding | — | — | — | — | — | |
| Common stock - $0.0001 par value; 400,000,000 and 100,000,000 shares authorized at September 30, 2025 and 2024, respectively; 83,513,442 and 71,552,402 shares issued and outstanding at September 30, 2025 and 2024, respectively | 8,351 | 7,155 | 167 | 6,750 | 242 | |
| Additional paid-in capital | 109 | 85 | — | 44 | — | |
| Accumulated deficit | −64 | −39 | −2 | −18 | 345,266 | |
| Total Stockholders Equity | 45 | 46 | −2 | 26 | 345,508 | |
| Total Liabilities and Stockholders Equity | 101 | 84 | 73 | 48 | 68 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Deferred income tax expense | 1 | 576,000 | — | 576,000 | — | |
| Inventory | −13 | −2 | — | — | — | |
| Prepaid expenses | — | −1 | 62,715 | −5 | −88,169 | |
| Accounts payable | 10 | 2 | — | 1 | — | |
| Accrued expenses | 4 | −259,071 | 349,051 | −801,754 | 25,988 | |
| Due to related party | 9 | 14 | — | — | — | |
| Net Cash (Used in) Provided By Operating Activities | −5 | 126,353 | −601,304 | — | −47,968 | |
| License payments | −6 | −5 | — | — | — | |
| Net Cash Used In Investing Activities | −6 | −5 | −1 | — | −67 | |
| Net proceeds from issuance of common stock | 15 | — | — | — | 66 | |
| Cash contributed by parent | — | 4 | — | — | — | |
| Merger, net | — | −3 | — | — | — | |
| Proceeds from issuance of note payable to related party | — | 4 | — | — | — | |
| Net Cash Provided By Financing Activities | 15 | 5 | 2 | — | 68 | |
| Net Change in Cash and Cash Equivalents | 4 | 112 | — | — | — | |
| IPR&D Milestones included in License Payable | — | 28 | — | — | — | |
| Capital Contribution of due to related party by parent | — | 33 | — | — | — | |
| Net Prepaid Manufacturing transferred to Inventory | 1 | 6 | — | — | — | |
| Interest Paid | 187,389 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CITIUS ONCOLOGY, INC.'s CIK number?
CITIUS ONCOLOGY, INC.'s SEC CIK number is 0001851484 (1851484). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CITIUS ONCOLOGY, INC.'s SEC filings?
All of CITIUS ONCOLOGY, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CITIUS ONCOLOGY, INC. last report earnings?
CITIUS ONCOLOGY, INC. (CTOR) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-057883). This is CITIUS ONCOLOGY, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is CITIUS ONCOLOGY, INC.'s most recent earnings 8-K?
CITIUS ONCOLOGY, INC.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001213900-26-057883. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CITIUS ONCOLOGY, INC.'s latest earnings 8-K →
Look up any company's CIK number →